Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript September 24, 2024 Operator: Good morning, and ...

Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate ...

Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with ...

Altamira’s Senior Management will hold an investor call today, Tuesday, September 24, 2024, at 8:30 a.m. EDT its business update and first half 2024 results. Founder, Chairman, and CEO Thomas Meyer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

today announced that its associate company Altamira Medica Ltd. has agreed with its partner Nuance Pharma, Shanghai, China (“Nuance”) to extend the territory covered by their exclusive ...

百慕大哈密尔顿 - Altamira Therapeutics Ltd. (NASDAQ:CYTO) 今日宣布，其关联公司Altamira Medica Ltd.的ISO 13485质量管理体系认证已扩展至生产过程。这一认证确认Altamira Medica的Bentrio鼻腔喷雾剂在设计、开发、生产和分销的整个周期中都符合国际标准。 ISO 13485标准是医疗器械行业质量管理体系的全球公认基准 ...

HAMILTON, Bermuda - 专注于RNA递送技术的生物制药公司Altamira Therapeutics Ltd. (NASDAQ:CYTO)宣布进行普通股和认股权证的公开发行,预计总募资额约为400万美元(未扣除配售代理费用和其他发行费用)。本次发行的定价为每股或每份预付认股权证0.72美元,包括A-1系列和A-2系列普通认股权证,行权价均为每股0.72美元。 A-1系列认股权证在发 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; ...